FY2013 FINANCIAL HIGHLIGHTS
Revenue increased 14.6% year on year, driven by rise in
number of client deliveries
* Net profit after tax surged 94.7% to S$13.5 million
* Excluding one off items, net profit grow 33.6% to S$11.8
million
* Gross profit margin increased slightly from 71% in
FY2012 to 73% in FY2013
* Strong balance sheet with cash and cash equivalents of
S$23.3 million and low gearing of 0.08x
* Recommend final dividend of 1.0 cent in addition to
interim dividend of 1.0 cent; total dividend of 2.0 cents
CORDLIFE - FROM 1 PRODUCT TO 3 PRODUCTS BUSINESSES
1. Cord Bank Banking - Main product
2. Umbilical Cord. Tissue Banking - Main product (Boost recurring income)
3. Metabolic Testing - Recently launched
POINTS TO NOTE FOR CORDLIFE:
1) Cordlife had grows from one product business to three products businesses.
2) The recently acquired oversea businesses are all already in operation for a number of years so there is no start-up cost to worry about.
3) Cordlife recently acquired oversea businesses had not contribute to FY 2013. The oversea businesses will contrbute for the coming financial years. (Oversea companies are in Hong Kong, India, Indonesia, Malaysia & Philippines)
4) Hong Kong growth may be affected by the recent policy of lost in business coming from mainly China but the company is using Hong Kong as a launching pad for mainland China business as in the recent partnership with Golden Meditech.
5) Cordlife able to generate positive cash-flow yearly and low gearing - ratio of 0.08x (See report)
6) It's 10% shares in China Cord Blood Corp. are investment portfolio. (Listed in NASDAQ)
7) FY 2013 financial hightlights, Cordlife revenue growth by 14.6% but net profit growth by 33.6% (Profit margin double it's revenue)
My personal believe is CORDLIFE is a promising growth stock. It maybe trading above PE 20x but the growth will very soon catch up with the share price. Profit growth of FY13 on one product at 33.6%. At this rate profit growth profit will double in 3 years. With the addition of umbilical cord tissue bank and add on to the recent metabolic testing and in addition to the oversea businesses I believe Cordlife future is very promising.
The recent shares placement at $1.25 and the buying interest by COOP International Lte & FIL Ltd give me the confidence to accumulate more Cordlife shares on price weakness.
(For more details see reports attached)
infopub.sgx.com/Apps?A=COW_CorporateAnno...M_2013_PPT_Final.pdf